TORONTO, May 14, 2015 /PRNewswire/ -- Brainsway, the leader in the development of advanced non-invasive treatments for brain disorders, announced today that new data demonstrating the efficacy of the company's Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) will be presented at the Society of Biological Psychiatry (SOBP) Annual Scientific Meeting on May 14 at the Fairmont Royal York Hotel in Toronto.
The new data on the treatment of OCD will also be presented at the American Psychiatric Association (APA) Annual Meeting on May 16 at the Metro Toronto Convention Centre.
Deep TMS is an outpatient therapy that utilizes a coil to generate brief magnetic fields at an amplitude similar to that used in magnetic resonance imaging (MRI). The therapy was introduced to the United States by Brainsway for treatment of Major Depressive Disorder (MDD) and has been used to treat more than 5,000 MDD patients in more than 70 U.S. clinics, including Harvard University, Mount Sinai Medical School and UC San Diego Medical Center.
Brainsway's Deep TMS therapy is cleared by the U.S. Food and Drug Administration (FDA) for the treatment of MDD and additional Deep TMS coils are currently being evaluated for the treatment of other indications, including ADHD and OCD.
"The current treatments for OCD and ADHD are limited; as a result, many patients are living with distressing symptoms for which Deep TMS offers the hope of relief," said Ronen Segal, chief operating officer of Brainsway. "The ability to treat these conditions by non-invasively stimulating deep structures of the brain is truly promising for patients who suffer from these disorders."
Brainsway's Deep TMS therapy is based on patents filed by the National Institutes of Health (NIH) and by Brainsway. Brainsway holds the exclusive license from the NIH for the patent and therapy. The company's U.S. headquarters are in Philadelphia.
To learn more about Deep TMS and to see the device, visit booth #1631 at the APA conference May 16 through 20.
Brainsway Ltd. is dedicated to the development and marketing of the Deep TMS (Transcranial Magnetic Stimulation) technology for the treatment of brain disorders. Brainsway's unique therapy is based on patents filed by the National Institutes of Health (NIH) and by the company. Brainsway holds the exclusive license from the NIH for the patent and technology. Brainsway's Deep TMS therapy has been cleared by the FDA for treatment of depression patients who do not respond to any number of medication treatments in the current depressive episode. The treatment has been enthusiastically received by the international academic community, with 60 clinical trials conducted in major institutions worldwide. For more information, please visit www.brainsway.com.